Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Circassia Itching To Transform Allergy Sector

Executive Summary

U.K. biotech Circassia has the first potential cat allergy vaccine to reach advanced clinical studies in Europe and the U.S., funded by a large round of VC financing completed in 2011. Its allergen-free technology could revolutionize the treatment of allergies.

You may also be interested in...



In Short Order, Merck And Stallergenes File BLAs For New Allergy Immunotherapies

Both Merck and French biotech Stallergenes have filed BLAs with FDA for approval of their respective grass allergy immunotherapies.

Backing New Index Fund, GSK, J&J Buy Into Asset-Centric Vision Of Biotech Future

Index Life VI is the first life-sciences-only fund for Index; GSK’s Moncef Slaoui and J&J’s Paul Stoffels are on scientific advisory board.

Allergy-Focused Circassia Raises £60m, Led by Imperial Innovations

Funding round is Europe's fifth-largest in over a decade, underscoring investor confidence in Circassia's T-cell vaccine technology.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054822

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel